化工社化工社 化学情報印刷レポート · 研究参考用
プラゼパム
7-クロロ-1-シクロプロピルメチル-5-(フェニル)-1H-1,4-ベンゾジアゼピン-2(3H)-オン · セントラッキス · セダプラン · プラゼパム · ベルストラン · 1-(シクロプロピルメチル)-5-(フェニル)-7-クロロ-1H-1,4-ベンゾジアゼピン-2(3H)-オン · 1-(シクロプロピルメチル)-5-[フェニル]-7-クロロ-1H-1,4-ベンゾジアゼピン-2(3H)-オン · 7-クロロ-1-(シクロプロピルメチル)-1,3-ジヒドロ-5-フェニル-2H-1,4-ベンゾジアゼピン-2-オン
識別子と物理属性
| CAS No. | 2955-38-6 |
|---|---|
| 分子式 | C19H17ClN2O |
| 平均分子量 | 324.8 g/mol |
| 単同位体質量 | 324.1029409 g/mol |
| SMILES | O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC1CC1 |
| InChIKey | MWQCHHACWWAQLJ-UHFFFAOYSA-N |
| PubChem CID | 4890 |
| ChEMBL | CHEMBL969 |
| ChEBI | CHEBI:8362 |
| EC No. | 220-975-8 |
| DTXSID | DTXSID4021181 |
| 現地名 | プラゼパム |
化学・物理的性質
| XLogP | 3.6 |
|---|---|
| 極性表面積 | 32.7 |
| 水素結合供与体数 | 0 |
| 水素結合受容体数 | 2 |
| 回転可能結合数 | 3 |
| 重原子数 | 23 |
| 形式電荷 | 0 |
| 複雑度 | 482 |
| LogP（分配係数） | 3.73 |
| 溶解度 | 3.99e-03 g/L0.25 g をアルコール R に溶解し、同じ溶媒で 10 mL に希釈します。溶液は透明 (2.2.1) で無色 (2.2.2、方法 II) でした。9.095mg/L(25℃) |
| 融点 | 145-146 °C145 - 146 °C145-146° |
| Physical Description | Solid |
| Kovats Retention Index | 2648265126242630265226762679269426382610265526412650.12620261926562746.92646.32633.22660.52685 |
| Collision Cross Section | 174 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)] |
| 沸点 | 538.5±50.0 °C(Predicted) |
| 密度 | 1.1660 (rough estimate) |
| 屈折率 | 1.5790 (estimate) |
| 引火点 | 11 °C |
| 貯蔵条件 | 2-8°C |
| 外観・状態 | Solid |
| pKa（酸解離定数） | pKa 2.94 (Uncertain) |
| 色 | White to Off-White |
| 主な用途 | 医薬品（低分子化合物） |
| InChI | 1S/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2 |
| InChIKey | MWQCHHACWWAQLJ-UHFFFAOYSA-N |
| SMILES | Clc1ccc2N(CC3CC3)C(=O)CN=C(c4ccccc4)c2c1 |
| EPAの化学物質情報 | 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl- (2955-38-6) |
安全性と法規制
| GHS 分類 | This chemical does not meet GHS hazard criteria for 33.3% (1 of 3) of reports.WarningH336 (66.7%): May cause drowsiness or dizziness [Warning Specific target organ toxicity, single exposureNarcotic effects]H361 (66.7%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]H362 (33.3%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]P203, P260, P261, P263, P264, P270, P271, P280, P304+P340, P318, P319, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 3 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Reported as not meeting GHS hazard criteria per 1 of 3 reports by companies.There are 2 notifications provided by 2 of 3 reports by companies with hazard statement code(s).Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| 規制情報 | DEA schedule IV controlled substance2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right. |
| その他の安全情報 | IMAP assessments - 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-: Human health tier I assessmentIMAP assessments - 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-: Environment tier I assessment |
| Hazard Classes and Categories | STOT SE 3 (66.7%)Repr. 2 (66.7%)Lact. (33.3%) |
| Treatment | General supportive measures should be employed, along with intravenous fluids, and an adequate airway maintained. Hypotension may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value. Flumazenil (Anexate) is a competitive benzodiazepine receptor antagonist that can be used as an antidote for benzodiazepine overdose. In particular, flumazenil is very effective at reversing the CNS depression associated with benzodiazepines but is less effective at reversing respiratory depression. Its use, however, is controversial as it has numerous contraindications. It is contraindicated in patients who are on long-term benzodiazepines, those who have ingested a substance that lowers the seizure threshold, or in patients who have tachycardia or a history of seizures. As a general rule, medical observation and supportive care are the mainstay of treatment of benzodiazepine overdose. Although benzodiazepines are absorbed by activated charcoal, gastric decontamination with activated charcoal is not beneficial in pure benzodiazepine overdose as the risk of adverse effects often outweigh any potential benefit from the procedure. It is recommended only if benzodiazepines have been taken in combination with other drugs that may benefit from decontamination. Gastric lavage (stomach pumping) or whole bowel irrigation are also not recommended. |
用途
用途
生化学用試薬、神経作用物質。
用途
ベンゾジアゼピン系化合物で す。GABA 受容体に作用し、中枢神経抑制作 用を示します。作用時間は、長時間型とされ ています。
用途
ベンゾジアゼピン系化合物で す。GABA受容体に作用し、中枢神経抑制作 用を示します。作用時間は、長時間型とされ ています。
説明
Prazepam (Item No. 18358) is an analytical reference material categorized as a benzodiazepine. Prazepam is regulated as a Schedule IV compound in the United States. This product is intended for research and forensic applications.
使用
Sedative-hypnotic.
一般的な説明
Prazepam, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepine-2-one(Verstran), has a long overall half-life. Extensive N-dealkylationoccurs to yield active nordazepam. 3-Hydroxylation ofboth prazepam and nordazepam occurs.